Article

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: data from a translational study.

2020-07-17

Abstract excerpt

<title>Abstract</title> <p><bold>Background.</bold> Etoposide phosphate (VP-16) is a topoisomerase 2 (TOP2) inhibitor that demonstrated limited activity in patients with metastatic castration-resistant prostate cancer (mCRPC). In our study, we investigated the sensitivity of prostate cancer (PCa) cells (LNCaP, 22Rv1, PC3, DU145, PDB and MDB) to VP-16 and the possible relationship between VP-16 activity and TOP2 e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 810890f9-a344-58da-8e71-464348d8b94b
DOI: 10.21203/rs.3.rs-42290/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: data from a translational study.DOI 10.21203/rs.3.rs-42290/v1Read

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.Semantic proximity Read

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read

PARP inhibitors in advanced prostate cancer: when to use them?Semantic proximity Read

[Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].Semantic proximity Read

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patientsSemantic proximity Read

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate CancerSemantic proximity Read

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor MicroenvironmentSemantic proximity Read

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive-variant prostate cancerSemantic proximity Read

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analysesSemantic proximity Read

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.Semantic proximity Read

Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancerSemantic proximity Read